Compass vows to press on with FDA application despite new trial request

RegulatoryNegative

AI Analysis

Summary

Compass Therapeutics received an FDA recommendation to conduct a new clinical study for its investigational drug targeting advanced biliary tract cancer, but the company plans to continue pursuing an approval pathway.

Outcome Details

FDA recommended conducting a new clinical study

Importance:6/10

Sentiment:

-0.40

FDAbiliary tract cancerclinical trialregulatory setback

Related Companies

$CMPS

Read the original article

Published by BioSpace on September 22, 2026 4:09 PM

Read Original